Acute myeloid leukemia (AML) proliferation in vivo is maintained by a small fraction of progenitor cells. These cells have been assumed t o express an immature phenotype and t o produce most colony-forming units (CFU-AML). For one case of AML (French-American-British [FAB] M1, normal cytogenetics), we examined the capacity of the CD34+ (25% of unseparated AML cells) and CD34-fractions t o initiate leukemia in severe combined immunodeficient (SCID) mice. In addition, the production of CFU-AML and nucleated cells (NC) of these subsets was investigated in long-term bone marrow culture (LTBMC). The frequencies of cobblestone area-forming cells (CAFC) were also estimated; early appearing cobblestone areas (CAS) are indicative of relatively mature progenitors and late CAS represent the progeny of primitive progenitors. In mice transplanted with CD34-(98% pure) or CD34+ (98% pure) grafts, similar AML cell growth was seen throughout an observation period of 106 days. The HE MALIGNANT cell population of acute myeloid leukemia (AML) is assumed to be maintained in vivo by a small fraction of clonogenic cells.' Analysis of this fraction so far has been hampered by lack of assays for long-term growth of AML. Long-term growth of normal human bone marrow can be shown in vitro, for example, by long-term bone marrow cultures (LTBMC). Clonogenic AML cells have mainly been studied as colony-forming units of AML ( C m -AML) in short-term colony assays. Although the immunophenotype of CFU-AML displayed considerable heterogeneity among patients and may be aberrant,*" clonogenic capacity is generally regarded to be associated with an immature phenotype. The appearance of CD38 and the loss of CD34 expression have been associated with the loss of clonogenic Recently, CD34 and CD38 expression of in vivo leukemia-initiating cells has been investigated in mice with severe combined immunodeficiency (SCID). In one case, leukemia was shown to be initiated in mice injected with the CD34'/ CD38-AML cell fraction." AML was not established from the AML fraction depleted of the CD34'/CD38-cells. The data suggest that the heterogeneous marker expression of AML allows for isolation of fractions containing high numbers of progenitors, similar to normal hematopoietic cells.
Acute myeloid leukemia (AML) proliferation in vivo is maintained by a small fraction of progenitor cells. These cells have been assumed t o express an immature phenotype and t o produce most colony-forming units (CFU-AML). For one case of AML (French-American-British [FAB] M1, normal cytogenetics), we examined the capacity of the CD34+ (25% of unseparated AML cells) and CD34-fractions t o initiate leukemia in severe combined immunodeficient (SCID) mice. In addition, the production of CFU-AML and nucleated cells (NC) of these subsets was investigated in long-term bone marrow culture (LTBMC). The frequencies of cobblestone area-forming cells (CAFC) were also estimated; early appearing cobblestone areas (CAS) are indicative of relatively mature progenitors and late CAS represent the progeny of primitive progenitors. In mice transplanted with CD34-(98% pure) or CD34+ (98% pure) grafts, similar AML cell growth was seen throughout an observation period of 106 days. The HE MALIGNANT cell population of acute myeloid leukemia (AML) is assumed to be maintained in vivo by a small fraction of clonogenic cells.' Analysis of this fraction so far has been hampered by lack of assays for long-term growth of AML. Long-term growth of normal human bone marrow can be shown in vitro, for example, by long-term bone marrow cultures (LTBMC). Clonogenic AML cells have mainly been studied as colony-forming units of AML ( C m -AML) in short-term colony assays. Although the immunophenotype of CFU-AML displayed considerable heterogeneity among patients and may be aberrant,*" clonogenic capacity is generally regarded to be associated with an immature phenotype. The appearance of CD38 and the loss of CD34 expression have been associated with the loss of clonogenic Recently, CD34 and CD38 expression of in vivo leukemia-initiating cells has been investigated in mice with severe combined immunodeficiency (SCID). In one case, leukemia was shown to be initiated in mice injected with the CD34'/ CD38-AML cell fraction." AML was not established from the AML fraction depleted of the CD34'/CD38-cells. The data suggest that the heterogeneous marker expression of AML allows for isolation of fractions containing high numbers of progenitors, similar to normal hematopoietic cells.
To examine long-term growth of AML cells, we used transplantation in SCID mice as well as the cobblestone areaforming cell (CAFC) assay, This assay allows for calculation of clonogenic cell frequencies in fractions of hematopoietic cells. The late appearing cobblestone areas (CAS) of normal hematopoiesis are considered stem cell progeny with longterm engraftment potential, whereas the early appearing CAS are assumed to be derived from more mature progenitors."
The capacity to initiate leukemia in vivo in SCID mice, the expression of CD34, and in vitro clonogenic growth were investigated in this study. For this purpose, CD34+ and CD34-cells of one AML case were transplanted into SCID mice and investigated by LTBMC, CAFC assay, and shortterm colony cultures. capacity t o establish long-term growth from the CD34-cells was confirmed by renewed outgrowth after retransplantation. In vitro, the CD34-fraction contained both immature and mature CAFCs and produced high numbers of CFU-AML and NC in LTBMC. The CD34' fraction produced only small numbers of CFU-AML, NC, and mature CAFCs. Therefore, the expression of CD34 and the content of CFU-AML were not associated with long-term growth of AML. However, similar frequencies of primitive CAFCs were observed in both fractions. Thus, both CD34-and CD34+ subsets of this AML sample contained immature progenitors with the capacity t o initiate long-term AML growth as characterized in vivo (in SCID mice) as well as in vitro (in CAFC assay), indicating asynchrony between functional and immunophenotypical maturation of AML progenitor cell compartments. 0 1996 by The American Society of Hematology.
MATERIALS AND METHODS

AML cells.
Peripheral blood (PB) samples were obtained after obtaining informed consent from a patient presenting with AML M1 diagnosed according to the criteria of the French-American-British Committee (FAB).'* Cytogenetics showed a normal karyogram. Mononuclear cells were isolated by Isopaque-Ficoll centrifugation. Subsequently, T cells were depleted by E-rosetting.13 The cells were cryopreserved in 10% dimethylsulfoxide, 20% heat-inactivated fetal calf serum (FCS), and Iscove's modified Dulbecco's medium (IMDM). After thawing by stepwise dil~tion,'~ viability assessed by trypan blue staining was always greater than 90%.
Flow cytometry. The samples were incubated with phycoerythrin (PE)-conjugated mouse monoclonal antibodies against CD13, CD33, CD38, CD34, or HLA-DR and fluorescein isothiocyanate (FITC)-conjugated antibodies against CD15, CD34, or CD45. Mouse IgG,-FITC-and mouse IgG,-PE-conjugated antibodies and samples from nontransplanted SCID mice were used as controls. The antibodies were obtained from Becton Dickinson (San Jose, CA). Fluorescence was measured using a FACSCAN flow cytometer and Lysis I1 software (Becton Dickinson Immunocytometry Systems). Erythrocytes and dead cells were excluded from analysis by gating on forward and orthogonal light scatter. Cells recovered from SCID mouse bone marrow (BM) staining simultaneously for CD33 and CD45 were counted as human myeloid cells. '5 In some cases, human cells were separated from the mouse BM using fluoresence-activated cell sorting. Cells were recovered from Preparation of CD34+ and CD34-fractions. AML cells were incubated with an IgG2A antibody against CD34 (MoAb 561") that was noncovalently linked to rat-antimouse IgG2a-conjugated immunomagnetic beads (Dynabeads; Dynal, Oslo, Norway). CD34' cells were eluted from the beads using a polyclonal antibody preparation directed against the Fab fragment of the CD34 antibody (Detachabead; D~n a l ) . '~ The eluted cell population was devoid of CD34 antibodies and was 98% CD34' as determined by FACS analysis after restaining with CD34-PE (HPCA-2; Beckton Dickinson; Fig  2B) . Nonbound cells were further depleted by a similar second incubation with the CD34 immunomagnetic beads. In the final CD34-fraction, 2% of the cells weakly stained with CD34-PE ( Fig 2C) in a FACScan reanalysis.
SCID mice and transplantation of AML. Female specific pathogen-free CB17 scidscid mice (5 to 8 weeks of age) were obtained from Harlan CPB (Austerlitz, The Netherlands), housed under pathogen-free conditions in a laminar air flow unit, and supplied with sterile food and acidified drinking water with 100 m g L ciprofloxacine (Bayer AG, Leverkusen, Germany). Before transplantation, the mouse plasma Ig level was determined with an enzyme-linked immunosorbent assay (ELISA) using a sheep antimouse antibody reacting with mouse IgG and IgM (Boehringer Mannheim Biochemica, Penzberg, Germany). Mice with plasma Ig levels greater than 40 pg/mL were excluded. Total body irradiation (TBI) at 3.5 G was delivered by a 137Cs source (Gammacell; Atomic Energy of Canada, Ottawa, Ontario, Canada) adapted for the irradiation of mice. Leukemic cells, suspended in 300 pL Hank's balanced salt solution (HBSS; GIBCO, Breda, The Netherlands), were injected intravenously (IV) into the lateral tail vein. This particular AML was known to proliferate in SCID mice without administration of human hematopoietic growth factors. '8 Tissue collections. SCID mice were killed by CO2 inhalation, followed by cervical dislocation in accordance with institutional animal research regulations. Cell suspensions were prepared from the BM and used for flow cytometry and the preparation of cytospin slides. Cytospin slides were stained with May-Griinwald Giemsa and morphology was microscopically evaluated.
Colony culture assay. Cells FSC dishes (Becton Dickinson) in 1 mL Dulbecco's modified Eagle's medium (DMEM; GIBCO, Gaithersburg, MD) containing 0.8% methylcellulose, 5% FCS, 1% bovine serum albumen (BSA), glutamine (2 mmol/L), insulin (10 pg/mL), linoleic acid, and cholesterol (1.5 X 10" mol/L), sodium selenite (1 X lo7 mol/L), nucleosides (each at 1 mg/mL), 2-mercaptoethanol (1 X IO4 mom), iron-saturated human transferrin (0.6 mg/mL), penicillin (100 U/mL), and streptomycin (850 pg/mL). Assays were performed either without hematopoietic growth factors or with granulocyte-macrophage colony-stimulating factor (GM-CSF; Behringwerke AG, Marburg, Germany; 5 ng/mL), interleukin-3 (E-3; Sandoz BV, Basel, Switzerland; 10 ng/mL), GM-CSF and IL-3, or stem-cell factor (SCF Immunex, Seattle, WA; 200 ng/mL), GM-CSF, and IL-3. LTBMC. LTBMC was performed as described previously.'' Briefly, confluent layers of the FBMD-l stromal cell line in 25-cm2 flasks were overlaid with either 10' unseparated AML cells or 10' CD34-cells or lo6 CD34' cells per flask. The cells were cultured in DMEM (GIBCO) supplemented with HEPES (3.5 mmol/L; Sigma, St Louis, MO), glutamine (2 mmol/L), sodium-selenite (10" mol/L), P-mercaptoethanol mol/L), 12.5% FCS, 12.5% horse serum (HS), and hydrocortisone 21-hemisuccinate (IO-' mol/L final concentration), in the presence of IL-3 (10 ng/mL) and G-CSF (20 ng/mL). IL-3 (10 ng/mL) and G-CSF (20 ng/mL) were added weekly to the cultures. Flask cultures of each fraction and of the unfractionated AML were set up in triplicate and maintained at 33°C for 50 or 63 days with weekly half-medium changes and therefore removal of only half of the nonadherent (NA) cells. The output of NA cells and CFU-AML output of individual flasks was determined every 2 weeks.
C A W ussuy. The CAFC assay was performed as previously described." Briefly, confluent stromal layers of FMBD-I cells in 96-wells plates were overlaid with isolated CD34', CD34-, or the unseparated AML cells in a limiting dilution setup. The medium was the same as used for LTBMC. Input values were 2,854 nucleated cells (NC) per well for unseparated and CD34-cells and 28,664 NC/well for CD34+ cells. Twelve dilutions twofold apart were used for each sample, with 15 replicate wells per dilution. The percentage of wells with at least one phase-dark hematopoietic clone of at least five cells (CA) beneath the stromal layer was determined about every 14 days and CAFC frequencies were calculated using Poisson statistics, as described.".*" RESULTS AML growth in SCID mice. Results of SCID mouse transplantations were obtained in four separate experiments using different graft sizes. Transplantation of 7.5 X lo6 of unseparated AML cells, the CD34' or the CD34-fraction, resulted in reproducible AML outgrowth as of day 35 ( Table  1) . The CD34-fraction, as well as unseparated AML cells and the CD34' fraction maintained AML growth in SCID mice during the latter period. Transplantation of 1 X lo6 AML cells resulted in reproducible outgrowth of AML between days 55 and 106, whereas earlier AML outgrowth was mainly below the level of detection ( Table 1) .
Graft failures were defined as a percentage of AML cells in the SCID mouse bone marrow smaller than 1%. Three For The percentages of human AML cells were determined on FACS scan analysis. Graft failures were defined as less than 1% AML cells in the Graft failures included as 0%.
t Values calculated on the basis of data from less than four engrafted mice.
BM.
graft failures occurred between days 55 and 106 among 42 transplanted mice, ie, in two instances among mic: transplanted with unseparated AML and in one recipient of the CD34-fraction. These three mice had each received a graft of 1 X lo6 cells. The mice were not evaluated at time points later than day 106.
Retransplantation of BM recovered from recipients of 30 X lo6 CD34-cells on day 28 resulted in regrowth of AML in two secondary recipients. The secondary grafts contained 4.0 X lo6 and 4.6 X lo6 AML cells. After transplantation of the latter secondary recipients, BM infiltration by AML cells was 1% at day 54 and 28% at day 95, respectively.
A cell dose titration ranging from 0.33 X lo6 to 30 X lo6 of unseparated AML cells showed a dose effect relationship between cell dose and engraftment of AML (Table 2) . Outgrowth of AML was not observed after transplantation of 9 X lo4 CD34+ cells (data not shown).
Flow cytometry. Expression of CD34 and CD38 of unseparated AML cells before transplantation is shown in Fig  1A. The AML cells were positive for CD33, CD45, HLADr CD13, and CD15. Expression of CD34 and CD38 was analyzed in the BM of all mice described. Irrespective of the initial graft, AML cells recovered from the BM of SCID mice were CD34-and stained homogeneously for CD38 (Fig 1B and C) . The CD34'/CD38-cells had converted to a CD34-/CD38+ phenotype after growth in the SCID mouse. BM cells containing more than 10% human cells were used for more extensive analysis with CD13, CD15, CD33, CD34, CD38, CD45, and HLADR. The latter analysis was performed on the BM of 22 mice that had received an unseparated graft (n = 8), a CD34+ graft (n = 6), or a CD34-graft (n = 6). Similar to the originally grafted AML cells, CD45' cells were also positive for CD33 and HLADr and most cells were positive for CD1 3 and CD15. The light scatter properties of the AML cells had not changed: a homogeneous population of cells with light scatter properties confined to the blast region. Flow cytometry did not show differences between AML cells recovered from mice transplanted with the CD34-fraction, the CD34' fraction, or unseparated AML cells.
Morphologic evuluation of cytospin prepurations. The BM of 12 mice was analyzed for morphology (4 transplanted with unseparated AML cells, 4 transplanted with the CD34' fraction, and 4 transplanted with the CD34-fraction). In addition, the BM of one secondary recipient in the retransplantation experiment was analyzed. In all cases, human cells in SCID recipients with AML growth appeared as large mononuclear cells with a large nucleus containing one or two nucleoli among normal mouse BM cells. The scant cytoplasm contained a limited number of azurophilic granulae (Fig 3) . The large cells were absent from normal mouse BM and the morphology was similar to the initial patient sample. Morphologic differences were not apparent between AML cells recovered from mice transplanted with the CD34+ fraction, the CD34 fraction, or unseparated AML.
Colony culture assuy of AML cell fractions. Almost all CFU-AML were recovered in the CD34-fraction and minimal numbers the CD34' fraction (Table 3) . Cultures were performed with fractions obtained in two separate experiments. No colonies were formed in the absence of growth factors. Uptake of tritiated thymidine in serum free culture" was not activated in the absence of growth factors (data not shown).
Colony culture assay of AML cells recovered from SCID recipients. The BM of the SCID mice was obtained at variable times after transplantation and inoculated in a colony assay to assess numbers of CFU-AML. CFU-AML were recovered from the SCID mice after transplantation until as late as day 106 (Table 4) . CFU-AML were derived from the BM of these recipients of unseparated AML cells, the CD34' and the CD34-fraction. Colony formation was not apparent in cultures without growth factors.
LTBMC. CD34-cells in the LTBMC flasks produced many nonadherent cells and CFU-AML (Fig 4A and B) .
In contrast, very low numbers of Cm-AML and NC were produced by CD34' cells. CFU-AML or nucleated cell production by the CD34-fraction or unseparated AML cells did not decline for the duration of the assay. CAFC assay. Frequency analysis of early and late CAS produced by the CD34-fraction, the CD34' fraction, or unseparated AML cells (Fig 5 ) showed that nearly all early CAS were produced by the CD34-fraction. The CD34' fraction produced 25 day-l2 CAs/lOs input NC (standard error of the mean [SEMI 3 . 3 , unseparated AML cells produced 303 day-12 CAS (SEM 44.7), and 25% of unseparated AML cells were CD34'. Thus, 98% of early CAS of unseparated AML cells were produced by the CD34-fraction. How- ever, late CAS appeared in similar frequencies after seeding of both fractions in culture. CAS from the CD34-and CD34-fraction were maintained until at least day 56.
DISCUSSION
We present here an analysis of the progenitor cell compartment of a single case of human AML using a variety of progenitor cell assays. Data from the SCID mouse model show that the CD34-fraction of AML cells had the same capacity to initiate and maintain long-term growth of AML in vivo as had the CD34' fraction. The CD34-fraction was capable of maintaining AML growth for more than 3 months and was also able to initiate renewed proliferation of AML after transfer to a second recipient. AML colony (CFU-AML) formation in a short-term colony assay of AML cells recovered from mice that had initially been transplanted with unseparated AML cells, the CD34-fraction, or the CD34' fraction in the presence of IL-3, GM-CSF, and SCF. The number of colonies is expressed per lo5 sorted human AML cells. Colonies were not observed in the absence of growth factors or in BM of untransplanted mice (data not shown). The outgrowth of AML after transplantation of CD34 grafts cannot be attributed to contaminating CD34' cells. The cell dose titration showed that more than 0.3 X 10' of unseparated AML cells (ie, more than 8 X lo4 CD34' cells) are required to obtain measurable AML growth. For extensive BM infiltration (>20%) at day 35, more than 3.3 X 10' of unseparated AML cells (ie, more than 83 X IO" CD34' cells) are required ( Table 2) . Contamination of CD34-grafts by CD34' cells was far below these levels, because the CD34-fractions were 98% pure. The leukemic origin of the cells expanding in the SCID mice was confirmed by morphologic examination and by the leukemic immunophenotype. In addition, proliferation of human hematopoietic cells was observed in the absence of exogenous hematopoe- tic growth factors. Under these circumstances, normal BM does not expand in SCID mice.'* Other investigators have reported one case of AML in which long-term growth capacity was restricted to the CD34+/CD38 fraction." In the latter case, the immunophenotype of the repopulating AML cells was identical to that of the fraction of normal BM that contains hematopoietic stem cells. However, our data show that the expression of CD34 and long-term leukemia-initiating capacity do not necessarily correlate and can be separated as independent characteristics of AML progenitors. The difference between these and previously published data is probably due to cellular heterogeneity of AML. This heterogeneity may become apparent when additional cases of AML are examined. As yet, only few cases of AML have been investigated as regards the distribution of AML cells with long-term capacity over phenotypically defined AML compartments.
Cases of AML proliferating in SCID mice without exogenous growth factor supply have been described by AML cells recovered from the SCID mice had retained an absolute dependence on hematopoietic growth factors as regards the colony-forming abilities in vitro. Therefore, there was no in vivo selection of an AML subclone in the SCID mice that is independent on IL-3. Interaction with the BM microenvironment or stimulation by mouse cytokines offer more likely explanations for the proliferative outgrowth of AML in SCID recipients.
In contrast to the similarities between the CD34' and the CD34-fractions with respect to in vivo growth, clear differences were shown in vitro. CFU-AML were almost entirely contained in the CD34-fraction (Table 3) . Both the CD34' and the CD34-fractions initiated long-term growth. Consistently, early CA production, an index of late progenitors, was mainly seen after seeding of CD34-cells in the CAFC assay (Fig 5) . Thus, the presence of CFU-AML or early CAFC in a particular fraction of AML cells does not For personal use only. on August 30, 2017. by guest www.bloodjournal.org From predict for long-term growth of AML. Similarly, the production of NC and CFU-AML in LTBMC was mainly observed in the CD34-fraction (Fig 4) . The latter two parameters therefore do not correlate with long-term growth of AML either.
The only in vitro property shared by the CD34+ and CD34-fractions was the presence of late CAFCs (Fig 5) . In normal hematopoiesis, late CAFCs are generally regarded as more primitive normal hematopoietic cells. Using chimeric mouse models, late CAFCs (weeks 4 to 8) have been shown to be correlate with normal stem cells that induce stable multilineage chimerism in vivo. In contrast, early CAFC (day 10) frequencies accurately reflect those of day-10 spleen colony-forming cells, which express transient repopulating ability in mice.24 For human hematopoiesis, it has been shown that late CAFCs are predominantly contained in the CD34+, Rhodamine 123'"'', HLA-DR'"" fraction, which is in agreement with previously reported long-term cultureinitiating cell characteristics." Similar to the late CAFCs of normal hematopoiesis, late CAFCs of the case of AML investigated here are cells with long-term growth capacity. This was shown by the long-term growth of leukemic late CAFCs in vitro in the CAFC assay and confirmed by the long-term growth of both fractions containing late CAFCs in SCID mice. Because other clonogenic assays (CFU-AML, LTBMC, and early CAFC formation in the CAFC assay) failed to correlate with long-term growth capacity in vivo, we conclude that the late-appearing CAFC is a highly immature cell observed in vitro in this case of AML.
The capacity to induce long-term growth is generally accepted as the parameter of choice for immaturity. The CD34' and CD34-fractions both contained these immature subsets. This is not observed in normal BM and may be a phenomenon that characterizes the maturation abnormality of this case of AML. Only CD34-cells were recovered from SCID mice transplanted with the CD34+ or CD34-fractions, indicating that the CD34+ and CD34-precursors both generated CD34-progeny. It should be noted that more mature progenitor cells such as CFU-AML and early CAFCs were observed in the CD34-fraction only. This indicates that the majority of more mature progenitor cells becomes CD34-.
In some cases, normal BM cells overgrow leukemic cells in LTBMC.25,26 The CD34+ fraction of this case of AML could have contained normal CD34+ precursors. However, these normal precursors would have produced CFU-GM and NCs at 4 weeks of culture.23
Thus, both CD34-and CD34+ subsets of this AML sample contained immature progenitors with the capacity to initiate long-term AML growth as identified in vivo as well as in vitro, indicating asynchrony between functional and immunophenotypical maturation of AML progenitor cell compartments. The capacity of AML subpopulations to initiate and maintain leukemia in vivo cannot be determined on the basis of the expression of CD34 or the production of CFU-AML.
